ClinicalTrials.gg
CompletedNCT07173738Updated Sep 15, 2025

Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide

A Phase 1 interventional study of BIA 5-1058 and Furosemide in Pulmonary Arterial Hypertension, sponsored by Bial - Portela C S.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years 2 months after the study started (first participant enrolled Jun 2018, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing zamicastat in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. zamicastat · Pulmonary Arterial Hypertension.

Enrollment
5th of 11
44 · median 44
Started
2018
with 6 others
Phase 1
9 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
11 of 11
Bial - Portela C S.A.

Among the 11 studies testing zamicastat in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 7 that started in 2018, is one of 9 in phase 1, and was the 11th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 11 studies testing zamicastat in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About zamicastat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing zamicastat in Pulmonary Arterial Hypertension as a file.
02

Study summary

The purpose of this study is:

  • To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK).
  • To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
Read the detailed description

This was an open-label, single-dose, fasted, 3-periods, fixed-sequence study separated by a washout period of 10 days or more in healthy volunteers.

Each healthy subject will participate in the study for approximately 3 months, including a 28-day screening period, 3 periods of 3.5 days and 4 nights (inpatient) with each dosage separated by a 10 day washout period and a follow-up visit. The inpatient period will be from Day -1 to Day 4 morning. Dosing will occur on Day 1 and subjects will remain in the clinic until 72 hours (h) after administration.

A Follow up visit will be performed 14 ± 2 days after discharge of the last period.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension (PAH)
  • BIA 5-1058
  • Zamicastat
  • Furosemide
  • Dopamine ß-hydroxylase (DßH) inhibitor
  • BIAL
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A signed and dated form before any study-specific screening procedure is performed;
  2. Males and Females subjects aged 18 to 55 years, inclusive;
  3. Non-smoker or ex-smokers for at least 3 months prior to screening;
  4. (BMI) between 18 and 30 kg/m2, inclusive;
  5. Subject with no history of previous allergy / sensitivity to BIA 5-1058/furosemide or any of the contained within the IMP(s);
  6. Negative tests for surface antigen (HBsAg), anti- virus antibodies (HCV Ab) and anti- antibodies (HIV-1 and HIV-2 Ab) at screening;
  7. Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period;
  8. Healthy as determined by the Investigator based on medical history, physical examination, , vital signs (systolic blood pressure (SBP) ≥ 90 mmHg and ≤ 140 mmHg, diastolic blood pressure (DBP) ≥ 50 mmHg and ≤ 90 mmHg) and digital 12-lead (ECG));
  9. Clinical laboratory test results clinically acceptable at screening and admission to each treatment period;

    If male:

  10. Male subjects and female partner willing to use 2 effective methods of , i.e., established method of contraception + condom, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of IMP.
  11. Refraining from donating sperm throughout the study and for 3 months after the last dose of IMP;

    If female:

  12. No by reason of surgery or at least 1 year (i.e., 12 months post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing;
  13. If of childbearing potential, using an effective non-hormonal method of contraception [intrauterine device; condom or occlusive cap (diaphragm or cervical or vault caps) with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he is the sole partner of that subject] for all the duration of the study and for 3 months after the last dose of IMP;
  14. Negative serum pregnancy test at screening and negative urine pregnancy test on admission of each treatment period).

Exclusion criteria

Exclusion Criteria:

  1. Any personal or family history of haemostatic disorder;
  2. Consumption of more than 21 units (14 units for female subjects) of alcohol a week [1 unit corresponds to 1 glass of 12% wine (10 cl), 1 glass of 45% pastis (2.5 cl), 1 glass of 40% whisky (2.5 cl), 1 glass of 12% champagne (10 cl), 1 glass of 18% aperitif drink (7 cl) or one 25-cl glass of 5% beer];
  3. Use of nicotine replacement products such as patches, gum and/or electronic cigarettes within 3 months prior to the screening visit;
  4. Significant infection or known inflammatory process at screening or admission to each treatment period;
  5. Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period;
  6. Symptomatic orthostatic hypotension [drop of > 20 mmHg in SBP and/or > 10 mmHg] in DBP when moving from supine to standing position, together with other symptoms, e.g. dizziness
  7. Previous use of BIA 5-1058;
  8. Use of any drug or participation in any clinical trial within 90 days or 5 half-life times, whichever is longer,
  9. Participation in more than 4 clinical trials within the 12 months prior to screening;
  10. Donation or reception of any blood or blood products within the 3 months prior to screening;
  11. Vegetarians, vegans or other medical dietary restrictions;
  12. Not able to communicate reliably with the Investigator;
  13. Unlikely to co-operate with the requirements of the study;
  14. Use of medicines within 28 days of initiation of treatment that may affect the safety or other study assessments, in the Investigator's opinion or intake of any of the prohibited medications.
  15. history or presence of respiratory, gastrointestinal, hepatic, renal, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders;
  16. Clinically relevant surgical history that could interfere with the pharmacokinetics of the trial medications;
  17. No medication will be permitted throughout the study, except for medications to treat adverse events (AEs).
  18. Subject has an abnormal hepatic function based on an overall assessment by the Investigator regarding medical history, physical examination and laboratory tests of hepatic function ( > 1times the (ULN), aspartate transaminase (AST) > 1times the ULN and total > 1times the ULN [confirmed by subsequent repeat]), as judged by the Principal Investigator. If a laboratory assessment is outside of the reference range at the local laboratory at the Screening Visit or baseline, the assessment may be repeated once as soon as possible and in any cases before enrolment to rule out laboratory error.
  19. Any clinically relevant findings in the laboratory tests, including any abnormality in the coagulation tests;
  20. History of alcoholism or drug abuse;
  21. Females who are currently breast feeding.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    BIA 5-1058

    Period 1: Single oral dose of BIA 5-1058 400 mg

    Drug: BIA 5-1058

  • Experimental
    Furosemide

    Period 2: 40 mg furosemide (single oral dose)

    Drug: Furosemide

  • Experimental
    BIA 5-1058 and Furosemide

    Period 3: 40 mg furosemide (single oral dose) concomitant with a single oral dose of BIA 5-1058 400 mg

    Drug: BIA 5-1058 and Furosemide

Interventions

  • During treatment period 1, a single oral dose of BIA 5-1058 (400 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.

    Also known as: Period 1

  • During treatment period 2, a single oral dose of furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.

    Also known as: Period 2

  • DrugBIA 5-1058 and Furosemide

    Drug page: PNU-100480

    During treatment period 3, a single oral dose of both investigational medicinal product (IMPs) BIA 5-1058 (400 mg) concomitantly with furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.

    Also known as: Period 3

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  2. Time to Cmax (Tmax)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  3. Elimination rate constant (kel)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  4. Terminal elimination half-life (t1/2)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  5. Area under the concentration-time curve (AUC) from time of dosing to last measurable concentration (AUC0-t)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  6. AUC extrapolated to infinity (AUC0-inf)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  7. Clearance (CL/F)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  8. Volume of distribution (Vz/F)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

  9. AUC% extrapolated (residual area)

    Will be calculated from the treatment periods 1, 2 and 3, days 1 to 4, BIA 5-1058 and furosemide concentration-time data

    Time frame: Up to 3 months

07

Study locations

1 site
  • Simbec Research Ltd (Simbec)
    Merthyr Tydfil, CF48 4DR, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Sep 2018, 2 months.

Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 2 months is below that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 15, 2025
StartActual
Jun 11, 2018
Primary completionActual
Sep 7, 2018
CompletionActual
Sep 7, 2018
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07173738
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Jun 11, 2018
Primary completion
Sep 7, 2018
Completion
Sep 7, 2018
Last update
Sep 15, 2025

Study contacts

Annelize Koch, Dr
principal investigator · Simbec Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zamicastat · Furosemide · PNU-100480

Start the discussion